Page 2 - Initiate Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Week in Review: January 22-26

From noninvasive brain stimulation for substance use disorders to updates from APSARD 2024, here are highlights from the week in Psychiatric Times.

United statesMargie balfourBrian jacksonUs centers for diseaseWorld federationOther mental health crisesInternational association for childCenters for diseaseConnections health solutionsUs food drug administrationNational suicide prevention lifelineDrug administrationAmerican professional societyPsychiatric timesRelated disorderDisease control

Coya Therapeutics (COYA) Announces Pipeline Expansion of COYA 302

Coya Therapeutics (COYA) Announces Pipeline Expansion of COYA 302
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Fred grossmanHowardh bermanCoya therapeutics incCoya therapeuticsChief medical officerInitiate phaseInitiated trialLongitudinal biomarkerLongitudinal biomarker data

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson s Disease in Addition to Amyotrophic Lateral Sclerosis -January 16, 2024 at 08:16 am EST

All three conditions share common hallmark of complex inflammatory pathways underlying disease pathophysiology that involve dysfunctional regulatory T cell biology which may limit efficacy of.

United statesHowardh bermanFred grossmanDavid beersJason thonhoffStanley appelNational institutes of healthHouston methodist research instituteCoya therapeutics incCoya therapeuticsChief medical officerInitiate phaseInitiated trialLongitudinal biomarkerLongitudinal biomarker dataInitiated trial topline

Zura Bio (ZURA) Reports Q3, Provides Update

Zura Bio (ZURA) Reports Q3, Provides Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMegank weinshankSteve zieglerSomeit sidhuZura bioBenaroya research instituteDrug administrationContract developmentManufacturing organizationZura bio limited nasdaqContract research organizationZura bio limitedChief executive officerUnited states foodThymic stromal lymphopoietinPress release

Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

-Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line.

United statesDavid epsteinRoger danseyDisitamab vedotinDrug administrationDevelopment rd expensesEuropean society of medical oncologyAmerica greenest companiesEuropean commissionSociety for immunotherapy of cancerExchange commissionCompany quarterly report on formSeagen incInternational conference on molecularEuropean commission approvesChief executive officer